异动解读|ImmunityBio, Inc.盘中下跌4.26%,财报逊预期与亏损扩大持续压制股价

行情直击
Nov 20

11月20日,ImmunityBio, Inc.盘中下跌4.26%,报6.3美元/股,成交额1314.39万美元。

消息面上,市场仍在消化公司此前披露的第三季度业绩不及预期影响,营收低于预期且亏损扩大,继续压制股价表现。

数据显示,公司第三季度营收4884.1万美元,低于市场预期的5925万美元;调整后每股亏损0.09美元,逊于预期的亏损0.08美元;每股净亏损扩大至0.18美元,高于上年同期的0.07美元。尽管Anktiva在以色列获批、欧洲完成首批患者治疗,且膀胱癌注册性试验达到主要终点,但仍未完全对冲财务压力。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10